Dasatinib is a second-generation tyrosine kinase inhibitor originally developed to treat chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. In recent years, dasatinib has gained attention as a senolytic agent for longevity applications, typically used in combination with quercetin to selectively eliminate senescent cells that accumulate with aging.
Dasatinib functions as a senolytic by targeting multiple kinase pathways that senescent cells rely on for survival. When combined with quercetin, it creates a powerful senolytic cocktail that can selectively induce apoptosis in senescent cells while sparing healthy cells. This mechanism makes it a promising intervention for age-related diseases and potentially extending healthspan.
- Senescent cell burden (D+Q) — ↓ in adipose/kidney tissues — C.[335][391]
- Physical function (pilot studies) — ↑ small — C.[334][346]
- Cognitive/mobility in at-risk older adults — feasibility shown; signals uncertain — C.[^334]
- Longevity in humans — Insufficient — F.
Tyrosine Kinase Inhibition:
- BCR-ABL fusion protein (Philadelphia chromosome)
- Src family kinases
- c-Kit receptor
- Ephrin receptors
- PDGFR (platelet-derived growth factor receptor)¹
Src Kinase Inhibition:
- Disrupts survival pathways in senescent cells
- Targets the PI3K/AKT survival pathway
- Inhibits focal adhesion kinase (FAK) signaling²
Combination with Quercetin:
- Dasatinib inhibits Src kinase-dependent survival pathways
- Quercetin inhibits anti-apoptotic proteins (BCL-xL, BCL-2)
- Synergistic effect creates selective toxicity for senescent cells³
Cellular Selectivity:
- Senescent cells are more dependent on survival pathways
- Normal cells have redundant survival mechanisms
- Creates therapeutic window for selective elimination⁴
Animal Models:
- Improved cardiovascular function in aged mice
- Enhanced physical function and mobility
- Reduced tissue inflammation and fibrosis
- Extended healthspan in multiple aging models⁵
Senescent Cell Clearance:
- 25-50% reduction in senescent cell burden in various tissues
- Improved tissue regeneration and function
- Reversal of some age-related phenotypes⁶
STAMINA Study (2025):
- 12 participants aged ≥65 at risk for Alzheimer's disease
- Protocol: 100 mg dasatinib + 1250 mg quercetin for 2 consecutive days every 2 weeks for 12 weeks
- Results: Feasible and safe; potential cognitive improvements correlated with reduced inflammation⁷
Diabetic Kidney Disease Study:
- Open-label Phase 1 pilot study
- 3-day oral course reduced senescent cell burden 11 days later
- Improved metabolic parameters and kidney function markers⁸
Idiopathic Pulmonary Fibrosis Trial:
- Phase I, single-blind, placebo-controlled pilot study
- Demonstrated feasibility and tolerability
- Some participants showed improved lung function⁹
Alzheimer's Disease Studies:
- Multiple Phase I trials completed
- Good safety profile demonstrated
- Mixed results on cognitive outcomes¹⁰
2024 Longitudinal Study:
- 19 participants received dasatinib + quercetin for 6 months
- Significant changes in first-generation epigenetic clocks
- Notable decrease in telomere length
- Mixed effects on different aging biomarkers¹¹
Studies have documented improvements in aging-related biomarkers:
- Inflammatory markers (TNF-α, IL-6, IL-1β)¹²
- Senescence-associated secretory phenotype (SASP) factors¹³
- Adipose tissue inflammation markers¹⁴
- Cardiovascular function parameters¹⁵
Dasatinib has a well-characterized safety profile from decades of use in cancer treatment. In senolytic applications using intermittent dosing, the safety profile appears more favorable than continuous cancer dosing, though specific long-term data for anti-aging use remains limited¹⁶.
Hematological Effects:
- Neutropenia (low white blood cells) - 21% of patients¹⁷
- Thrombocytopenia (low platelets) - 10-19% of patients¹⁸
- Anemia (low red blood cells)¹⁹
- Usually reversible with dose modification²⁰
Gastrointestinal Effects:
- Diarrhea (common)²¹
- Nausea and vomiting²²
- Abdominal pain²³
- Generally mild to moderate severity²⁴
Constitutional Symptoms:
- Fatigue and weakness²⁵
- Headache²⁶
- Fever²⁷
- Muscle and joint pain²⁸
Skin and Soft Tissue:
- Skin rash²⁹
- Swelling (edema) in legs, arms, and face³⁰
- Usually manageable with supportive care³¹
Pulmonary Complications:
- Pleural effusion (fluid around lungs) - 18% in some studies³²
- Pulmonary arterial hypertension (PAH) - rare but serious³³
- Pulmonary edema³⁴
- Dyspnea (difficulty breathing)³⁵
Cardiovascular Effects:
- QT interval prolongation³⁶
- Heart failure (rare)³⁷
- Cardiac arrhythmias³⁸
- Requires cardiac monitoring³⁹
Bleeding Complications:
- Hemorrhage (bleeding)⁴⁰
- Increased bleeding risk due to platelet effects⁴¹
- GI bleeding (uncommon)⁴²
Renal Complications:
- Nephrotic syndrome (rare)⁴³
- Kidney function impairment⁴⁴
- Usually reversible with discontinuation⁴⁵
Senolytic Protocol Safety:
- Lower total drug exposure than cancer treatment
- Reduced incidence of chronic side effects
- Most adverse events are mild and transient⁴⁶
Monitoring Requirements:
- Complete blood count before each cycle
- Liver and kidney function tests
- Cardiac assessment if risk factors present⁴⁷
- Hypersensitivity to dasatinib or its components⁴⁸
- Pregnancy and breastfeeding⁴⁹
- Severe hepatic impairment⁵⁰
Cardiac Conditions:
- Pre-existing QT prolongation⁵¹
- Congenital long QT syndrome⁵²
- Uncontrolled heart failure⁵³
- Recent myocardial infarction⁵⁴
Pulmonary Conditions:
- Pre-existing pulmonary hypertension⁵⁵
- Severe lung disease⁵⁶
- History of recurrent pleural effusions⁵⁷
Hematological Conditions:
- Severe cytopenias⁵⁸
- Active bleeding disorders⁵⁹
- Recent major surgery⁶⁰
Elderly Patients:
- May require dose adjustments
- Increased monitoring for side effects
- Consider comorbidities and drug interactions⁶¹
Renal Impairment:
- Dose adjustment may be necessary
- Monitor kidney function closely⁶²
Hepatic Impairment:
- Contraindicated in severe hepatic impairment
- Dose reduction in moderate impairment⁶³
¶ Standard Senolytic Protocol (D+Q)
Dasatinib + Quercetin Combination:
- Dasatinib: 100 mg orally
- Quercetin: 1000-1250 mg orally
- Given for 2 consecutive days every 2 weeks
- Duration: 12-24 weeks initially⁶⁴
Alternative Protocols:
- Monthly 3-day cycles
- Lower dose protocols for sensitive patients
- Extended protocols for research applications⁶⁵
Pre-treatment Assessment:
- Complete medical history and physical exam
- Complete blood count with differential
- Comprehensive metabolic panel
- Liver function tests
- Electrocardiogram⁶⁶
During Treatment:
- CBC before each cycle
- Monthly metabolic panels
- Cardiac monitoring if indicated
- Symptom assessment⁶⁷
Post-treatment Follow-up:
- Recovery assessment
- Long-term safety monitoring
- Efficacy biomarker evaluation⁶⁸
CYP3A4 Inhibitors:
- Ketoconazole, itraconazole
- Clarithromycin, erythromycin
- Grapefruit juice
- May increase dasatinib levels significantly⁶⁹
CYP3A4 Inducers:
- Rifampin, phenytoin
- Carbamazepine, St. John's wort
- May reduce dasatinib effectiveness⁷⁰
QT-Prolonging Medications:
- Amiodarone, sotalol
- Haloperidol, ziprasidone
- Increased risk of arrhythmias⁷¹
Anticoagulants:
- Warfarin, heparin
- Increased bleeding risk
- Monitor INR closely⁷²
Proton Pump Inhibitors:
- May reduce dasatinib absorption
- Consider H2 blockers instead⁷³
¶ Cost and Accessibility
- Dasatinib (generic): $50-200 per cycle
- Quercetin supplement: $20-50 per cycle
- Monitoring costs: $200-500 per cycle
- Total monthly cost: $150-400⁷⁴
- Generic dasatinib widely available
- Requires prescription from qualified physician
- Limited to research settings or specialized clinics
- Off-label use for anti-aging applications⁷⁵
- Limited long-term safety data for senolytic use
- Optimal dosing protocols not established
- Individual variation in response not characterized
- Limited data on combination with other interventions⁷⁶
- FDA-approved only for cancer treatment
- Anti-aging applications are off-label use
- No standardized protocols for longevity applications
- Requires medical supervision⁷⁷
- Larger randomized controlled trials
- Biomarker-guided therapy protocols
- Combination with other senolytics
- Long-term safety and efficacy studies⁷⁸
- Optimized senolytic combinations
- Personalized dosing strategies
- Novel delivery systems
- Tissue-specific senolytic approaches⁷⁹
Dasatinib represents a promising senolytic intervention for longevity applications when used in combination with quercetin. While preliminary clinical data suggests good tolerability with intermittent dosing, the therapy requires careful medical supervision due to potential serious adverse events. The senolytic field is rapidly evolving, and dasatinib may serve as an important bridge therapy while next-generation senolytics are developed.
- Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47(27):6658-6661.
- Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015;14(4):644-658.
- Zhu Y, Tchkonia T, Fuhrmann-Stroissnigg H, et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell. 2016;15(3):428-435.
- Kirkland JL, Tchkonia T. Senolytic drugs: from discovery to translation. J Intern Med. 2020;288(5):518-536.
- Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and increase lifespan in old age. Nat Med. 2018;24(8):1246-1256.
- Zhu Y, Doornebal EJ, Pirtskhalava T, et al. New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463. Aging (Albany NY). 2017;9(3):955-963.
- Justice JN, Niedernhofer LJ, Robbins PD, et al. A pilot study of senolytics to improve cognition and mobility in older adults at risk for Alzheimer's disease. eBioMedicine. 2025;101:105056.
- Hickson LJ, Langhi Prata LGP, Bobart SA, et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019;47:446-456.
- Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: results of a first-in-human, open-label, pilot study. EBioMedicine. 2019;40:554-563.
- Gonzales MM, Garbarino VR, Marques Zilli E, et al. Senolytic therapy to modulate the progression of Alzheimer's disease (SToMP-AD): a pilot clinical trial. J Prev Alzheimers Dis. 2022;9(1):22-29.
- Raffaele M, Kovacovicova K, Frohlich J, et al. Exploring the effects of dasatinib, quercetin, and fisetin on DNA methylation clocks: a longitudinal study on senolytic interventions. Aging (Albany NY). 2024;16(3):2317-2336.
- Xu M, Tchkonia T, Ding H, et al. JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age. Proc Natl Acad Sci U S A. 2015;112(46):E6301-E6310.
- Tchkonia T, Zhu Y, van Deursen J, et al. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest. 2013;123(3):966-972.
- Palmer AK, Xu M, Zhu Y, et al. Targeting senescent cells alleviates obesity-induced metabolic dysfunction. Aging Cell. 2019;18(3):e12950.
- Roos CM, Zhang B, Palmer AK, et al. Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice. Aging Cell. 2016;15(5):973-977.
- Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events. Ther Adv Hematol. 2010;1(1):7-17.
- Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305(5682):399-401.
- Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354(24):2531-2541.
- Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 2007;109(12):5143-5150.
- Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007;109(6):2303-2309.
- Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260-2270.
- Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251-2259.
- Radich JP, Kopecky KJ, Appelbaum FR, et al. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood. 2012;120(19):3898-3905.
- Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014;123(4):494-500.
- Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333-2340.
- Hughes TP, Saglio G, Quintás-Cardama A, et al. BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase. Leukemia. 2015;29(9):1832-1838.
- Shah NP, Rousselot P, Schiffer C, et al. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol. 2016;91(9):869-874.
- Quintas-Cardama A, Kantarjian H, Jones D, et al. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood. 2007;109(2):497-499.
- Porkka K, Khoury HJ, Paquette RL, et al. Dasatinib 100 mg once daily minimizes the incidence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer. 2010;116(2):377-386.
- de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26(20):3358-3363.
- Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25(25):3908-3914.
- Ibid.
- Montani D, Bergot E, Günther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125(17):2128-2137.
- Rasheed W, Flaim B, Seymour JF. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res. 2009;33(6):861-864.
- Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25(25):3908-3914.
- Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf. 2013;36(5):295-316.
- Quintas-Cardama A, Han X, Kantarjian H, et al. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood. 2009;114(2):261-263.
- Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf. 2013;36(5):295-316.
- Ibid.
- Quintas-Cardama A, Han X, Kantarjian H, et al. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood. 2009;114(2):261-263.
- Ibid.
- Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260-2270.
- Redaelli S, Piazza R, Rostagno R, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol. 2009;27(3):469-471.
- Ibid.
- Vaz de Castro PA, Bitencourt R, Saldanha AC, et al. Dasatinib-induced nephrotic syndrome in chronic myeloid leukemia. J Oncol Pharm Pract. 2015;21(1):61-64.
- Justice JN, Niedernhofer LJ, Robbins PD, et al. A pilot study of senolytics to improve cognition and mobility in older adults at risk for Alzheimer's disease. eBioMedicine. 2025;101:105056.
- Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354(24):2531-2541.
- Bristol-Myers Squibb. Sprycel (dasatinib) prescribing information. 2021.
- Ibid.
- Ibid.
- Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf. 2013;36(5):295-316.
- Ibid.
- Ibid.
- Ibid.
- Montani D, Bergot E, Günther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125(17):2128-2137.
- Ibid.
- Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25(25):3908-3914.
- Bristol-Myers Squibb. Sprycel (dasatinib) prescribing information. 2021.
- Ibid.
- Ibid.
- Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333-2340.
- Bristol-Myers Squibb. Sprycel (dasatinib) prescribing information. 2021.
- Ibid.
- Justice JN, Niedernhofer LJ, Robbins PD, et al. A pilot study of senolytics to improve cognition and mobility in older adults at risk for Alzheimer's disease. eBioMedicine. 2025;101:105056.
- Hickson LJ, Langhi Prata LGP, Bobart SA, et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019;47:446-456.
- Bristol-Myers Squibb. Sprycel (dasatinib) prescribing information. 2021.
- Ibid.
- Justice JN, Niedernhofer LJ, Robbins PD, et al. A pilot study of senolytics to improve cognition and mobility in older adults at risk for Alzheimer's disease. eBioMedicine. 2025;101:105056.
- Bristol-Myers Squibb. Sprycel (dasatinib) prescribing information. 2021.
- Ibid.
- Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf. 2013;36(5):295-316.
- Bristol-Myers Squibb. Sprycel (dasatinib) prescribing information. 2021.
- Ibid.
- GoodRx. Dasatinib prices, coupons, and patient assistance programs. 2024.
- Justice JN, Niedernhofer LJ, Robbins PD, et al. A pilot study of senolytics to improve cognition and mobility in older adults at risk for Alzheimer's disease. eBioMedicine. 2025;101:105056.
- Kirkland JL, Tchkonia T. Senolytic drugs: from discovery to translation. J Intern Med. 2020;288(5):518-536.
- Bristol-Myers Squibb. Sprycel (dasatinib) prescribing information. 2021.
- Kirkland JL, Tchkonia T. Senolytic drugs: from discovery to translation. J Intern Med. 2020;288(5):518-536.
- Niedernhofer LJ, Robbins PD. Senotherapeutics for healthy ageing. Nat Rev Drug Discov. 2018;17(5):377.